Ocular Therapeutix patents expiration
1. Dextenza patents expiration
DEXTENZA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9254267 | OCULAR THERAPEUTIX | Composite hydrogel drug delivery systems |
Sep, 2024
(4 months from now) | |
| US8563027 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
Feb, 2030
(5 years from now) | |
| US8409606 | OCULAR THERAPEUTIX | Drug delivery through hydrogel plugs |
May, 2030
(6 years from now) | |
| US11458041 | OCULAR THERAPEUTIX | Punctal plug and bioadhesives |
Nov, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-876) | Oct 07, 2024 |
| New Indication(I-800) | Jun 20, 2022 |
| New Product(NP) | Nov 30, 2021 |
Drugs and Companies using DEXAMETHASONE ingredient
Market Authorisation Date: 30 November, 2018
Treatment: Dextenza is approved for the treatment of ocular pain following ophthalmic surgery; Treatment of ocular inflammation and pain following ophthalmic surgery
Dosage: INSERT;OPHTHALMIC
More Information on Dosage
DEXTENZA family patents
